# FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Source: https://onco.cc/trials/nct03678428/  
OnCo record `nct03678428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Irinotecan, Floxuridine, Leucovorin, Fluorouracil and Oxaliplatin in Colorectal cancer, run by Sun Yat-sen University, recorded as terminated on the registry.

## Summary

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM is a phase 3 interventional study registered as NCT03678428 by Sun Yat-sen University, with 92 participants recorded, started 2021-12-31 and due to reach its primary completion in 2022-10-31. Interventions recorded: Irinotecan, Oxaliplatin HAI, Floxuridine, Leucovorin, 5-FU, Oxaliplatin. Conditions recorded: Metastatic Colorectal Cancer, Liver Metastases.

Linked to the drug Floxuridine because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03678428
- Phase: 3
- Setting: FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
- Sponsor: Sun Yat-sen University
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT03678428: https://clinicaltrials.gov/study/NCT03678428

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Floxuridine](https://onco.cc/drugs/floxuridine/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct03678428.json